ciglitazone has been researched along with Asthma in 9 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Asthma: A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In the presence of 5% FBS, PPARgamma and cyclin D1 expression decreased over time in non-asthmatic cells but increased in asthmatic cells (compared with sub-confluent cells)." | 7.76 | Differential expression of peroxisome proliferator activated receptor gamma and cyclin D1 does not affect proliferation of asthma- and non-asthma-derived airway smooth muscle cells. ( Black, JL; Burgess, JK; Lau, JY; Moir, LM; Oliver, BG, 2010) |
| "In the presence of 5% FBS, PPARgamma and cyclin D1 expression decreased over time in non-asthmatic cells but increased in asthmatic cells (compared with sub-confluent cells)." | 3.76 | Differential expression of peroxisome proliferator activated receptor gamma and cyclin D1 does not affect proliferation of asthma- and non-asthma-derived airway smooth muscle cells. ( Black, JL; Burgess, JK; Lau, JY; Moir, LM; Oliver, BG, 2010) |
| "We used a mouse model of asthma induced by sensitization and airway challenge with ovalbumin." | 3.72 | Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. ( Capron, M; Dombrowicz, D; Honda, K; Marquillies, P, 2004) |
| "Ciglitazone has been shown to be dependent on NF-κB- and STAT3-related pathways, thus, the PPAR-γ agonist may have therapeutic potential for the treatment of airway remodelling in asthma." | 1.91 | Anti-fibrotic effect of ciglitazone in HRV-induced airway remodelling cell model. ( Pawliczak, R; Wieczfinska, J, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (77.78) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Wieczfinska, J | 1 |
| Pawliczak, R | 1 |
| Rhee, CK | 1 |
| Lee, SY | 1 |
| Kang, JY | 1 |
| Kim, SJ | 1 |
| Kwon, SS | 1 |
| Kim, YK | 1 |
| Park, SH | 1 |
| Lau, JY | 1 |
| Oliver, BG | 1 |
| Moir, LM | 1 |
| Black, JL | 1 |
| Burgess, JK | 1 |
| Woerly, G | 1 |
| Honda, K | 2 |
| Loyens, M | 1 |
| Papin, JP | 1 |
| Auwerx, J | 1 |
| Staels, B | 1 |
| Capron, M | 2 |
| Dombrowicz, D | 2 |
| Mueller, C | 1 |
| Weaver, V | 1 |
| Vanden Heuvel, JP | 1 |
| August, A | 1 |
| Cantorna, MT | 1 |
| Hammad, H | 1 |
| de Heer, HJ | 1 |
| Soullié, T | 1 |
| Angeli, V | 1 |
| Trottein, F | 1 |
| Hoogsteden, HC | 1 |
| Lambrecht, BN | 1 |
| Marquillies, P | 1 |
| Fainaru, O | 1 |
| Shseyov, D | 1 |
| Hantisteanu, S | 1 |
| Groner, Y | 1 |
| Stengel, PW | 1 |
| Zeckner, DJ | 1 |
| Guo, WK | 1 |
| Wolos, JA | 1 |
| Snyder, DW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of the PPARy Agonist Rosiglitazone on Airway Hyperreactivity[NCT00614874] | Phase 2 | 16 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Fraction Exhaled Nitric oxide was measured on each visit prior to bronchoprovocation by chemiluminescence using an analyzer. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | parts per billion (Mean) | |
|---|---|---|
| Baseline | 12 weeks | |
| Rosiglitazone | 48 | 41 |
FEV1 in liters (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | Liters (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 2.95 | 3.04 |
Spirometry was performed on each visit according to American Thoracic Society guidelines. FEV1 percent predicted was measured. (NCT00614874)
Timeframe: patients were assessed at baseline and 12 weeks
| Intervention | percent predicted (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 82 | 85 |
PC20 is the concentration of methacholine at which patients had a decrease in Forced Expiratory Volume in one second (FEV1) of 20% (NCT00614874)
Timeframe: patients were assessed at baseline and at 12 weeks
| Intervention | mg/mL (Mean) | |
|---|---|---|
| Baseline | Week 12 | |
| Rosiglitazone | 3.27 | 8.71 |
9 other studies available for ciglitazone and Asthma
| Article | Year |
|---|---|
Anti-fibrotic effect of ciglitazone in HRV-induced airway remodelling cell model.
Topics: Airway Remodeling; Asthma; Fibrosis; Heart Rate; Humans; NF-kappa B; PPAR gamma; Rhinovirus; Thiazol | 2023 |
Effect of peroxisome proliferator-activated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
Topics: Administration, Intranasal; Animals; Anti-Asthmatic Agents; Asthma; Bronchi; Bronchial Provocation T | 2009 |
Differential expression of peroxisome proliferator activated receptor gamma and cyclin D1 does not affect proliferation of asthma- and non-asthma-derived airway smooth muscle cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Androstadienes; Asthma; Bronchi; Bronchodilator Agents; | 2010 |
Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.
Topics: Anilides; Animals; Asthma; Chemotaxis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation | 2003 |
Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma.
Topics: Administration, Oral; Animals; Antigen-Antibody Complex; Asthma; Cells, Cultured; Cytokines; Female; | 2003 |
Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma.
Topics: Anilides; Animals; Asthma; Cell Movement; Cytokines; Dendritic Cells; Disease Models, Animal; Eosino | 2004 |
Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model.
Topics: Animals; Anti-Asthmatic Agents; Asthma; Female; Immunohistochemistry; Lung; Mice; Mice, Inbred BALB | 2004 |
Accelerated chemokine receptor 7-mediated dendritic cell migration in Runx3 knockout mice and the spontaneous development of asthma-like disease.
Topics: Animals; Asthma; Cell Movement; Core Binding Factor Alpha 3 Subunit; Dendritic Cells; DNA Primers; F | 2005 |
Methacholine-induced pulmonary gas trapping in a mouse model of allergic asthma: effect of inhaled budesonide and ciglitazone.
Topics: Administration, Inhalation; Airway Obstruction; Animals; Anti-Asthmatic Agents; Asthma; Bronchial Hy | 2008 |